Ophthotech Corp Cmn (OPHT) 55.88 $OPHT
Ophthotech Corporation to Present at the Goldman Sachs 37th Annual Global Healthcare Conference
BusinessWire - Tue May 31, 6:30AM CDT
Ophthotech Corporation (NASDAQ:OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present at the Goldman Sachs 37th Annual Global Healthcare Conference in Rancho Palos Verdes, California on Tuesday June 7, 2016 at 8:40 a.m. PT (11:40 a.m. ET).
OPHT: 55.88 (+1.72)
What to Look for in These Biotech Stocks? Threshold Pharma, Seattle Genetics, Chiasma, and Ophthotech
PR Newswire - Wed May 18, 7:38AM CDT
The Biotech industry continues to face a wave of challenges, but it does not mean that there are no opportunities ahead. Today, ActiveWallSt.com has on its list these four equities: Threshold Pharmaceuticals Inc. (NASDAQ: THLD), Seattle Genetics Inc. (NASDAQ: SGEN), Chiasma Inc. (NASDAQ: CHMA), and Ophthotech Corp. (NASDAQ: OPHT). Sign up now to receive our free insights and trading alerts at:
SGEN: 40.07 (+0.96), OPHT: 55.88 (+1.72), THLD: 0.41 (+0.03), CHMA: 2.74 (+0.19)
pSivida CEO to Present at 2016 International Symposium of Ocular Pharmacology and Therapeutics
GlobeNewswire - Wed May 04, 7:00AM CDT
pSivida Corp. (NASDAQ
SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that Dr. Paul Ashton, president and CEO, will present "Changing the Treatment Paradigm through Innovative Drug Delivery" at the International Symposium of Ocular Pharmacology and Therapeutics (ISOPT) on Sunday, May 8, 2016 in Paris.
OPHT: 55.88 (+1.72), PSDV: 3.20 (+0.26), PVA: 0.15 (-0.04)
Ophthotech reports 1Q loss
Automated Insights - Wed May 04, 6:38AM CDT
NEW YORK (AP) _ Ophthotech Corp. (OPHT) on Wednesday reported a first-quarter loss of $36.3 million, after reporting a profit in the same period a year earlier.
OPHT: 55.88 (+1.72)
Ophthotech Reports First Quarter 2016 Financial and Operating Results
BusinessWire - Wed May 04, 6:30AM CDT
Ophthotech Corporation (Nasdaq:OPHT) today announced financial results for the first quarter ended March 31, 2016 and provided an update on the Company's business and product development programs.
OPHT: 55.88 (+1.72)
Will AVEO Pharmaceuticals (AVEO) Surprise in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue May 03, 5:42PM CDT
AVEO Pharmaceuticals (AVEO) is expected to report first-quarter 2016 results on Mar 5.
ZTS: 47.90 (+0.57), OPHT: 55.88 (+1.72), AVEO: 0.98 (-0.01), NVS: 80.67 (+0.96)
Ophthotech Corporation to Report First Quarter 2016 Financial Results and Host Conference Call on Wednesday, May 4, 2016
BusinessWire - Tue Apr 26, 6:30AM CDT
Ophthotech Corporation (Nasdaq:OPHT) today announced that it will report its first quarter 2016 financial results on Wednesday, May 4, 2016. Following the announcement, Ophthotech's management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss the Company's financial results and provide a general business update.
OPHT: 55.88 (+1.72)
AVEO Gives AV-203 Ex-U.S. Rights to CANbridge Life Sciences
Zacks Equity Research - Zacks Investment Research - Wed Mar 23, 3:25AM CDT
AVEO Pharmaceuticals (AVEO) struck an exclusive collaboration and license agreement granting CANbridge Life Sciences rights to AV-203 outside North America.
BIIB: 238.62 (+4.02), OPHT: 55.88 (+1.72), AVEO: 0.98 (-0.01), NVS: 80.67 (+0.96)
Ophthotech Corporation to Present at Barclays Global Healthcare Conference 2016
BusinessWire - Tue Mar 08, 6:30AM CST
Ophthotech Corporation (NASDAQ:OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the Barclays Global Healthcare Conference 2016 in Miami on Tuesday, March 15, 2016 at 10:45 a.m. Eastern Time.
OPHT: 55.88 (+1.72)
Will AVEO (AVEO) Surprise Estimates in Q4 Earnings Again?
Zacks Equity Research - Zacks Investment Research - Wed Mar 02, 3:45PM CST
AVEO Pharmaceuticals (AVEO), which is expected to report fourth-quarter 2015 results on Mar 4, had recorded a positive earnings surprise of 200% last quarter.
BDSI: 2.39 (+0.06), OPHT: 55.88 (+1.72), AVEO: 0.98 (-0.01), NVS: 80.67 (+0.96)
Why Ophthotech Corporation Shares Tumbled 31% in January
Todd Campbell, The Motley Fool - Motley Fool - Sat Feb 06, 7:40AM CST
Source: Flickr user Luis Gustavo Zamudio A. W hat: Despite kicking off new trials in dry age-related macular degeneration, shares in Ophthotech Corporation dropped 31% in January, according to S&P Capital IQ. So what: In January,...
OPHT: 55.88 (+1.72), REGN: 357.14 (+5.22), NVS: 80.67 (+0.96)
Ophthotech Corporation to Present at the LEERINK Partners 5th Annual Global Healthcare Conference
BusinessWire - Wed Feb 03, 6:30AM CST
Ophthotech Corporation (NASDAQ:OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the LEERINK Partners 5th Annual Global Healthcare Conference in New York City on Wednesday, February 10, 2016 at 11:05 a.m. Eastern Time.
OPHT: 55.88 (+1.72)
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review 2015
M2 - Fri Jan 29, 10:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/rfl587/wet_neovascular) has announced the addition of the "Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Wet (Neovascular / Exudative) Macular Degeneration Overview - Therapeutics Development - Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration - Overview - Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration - Comparative Analysis - Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics under Development by Companies - Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics under Investigation by Universities/Institutes - Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Wet (Neovascular / Exudative) Macular Degeneration - Products under Development by Companies - Wet (Neovascular / Exudative) Macular Degeneration - Products under Investigation by Universities/Institutes - Wet (Neovascular / Exudative) Macular Degeneration - Companies Involved in Therapeutics Development Companies Mentioned: - Aciont Inc. - Allergan Plc - Amakem NV - Apellis Pharmaceuticals, Inc. - Apexigen, Inc. - Applied Genetic Technologies Corporatio - Avalanche Biotechnologies, Inc. - Benitec Biopharma Limited - BIOCAD - Boehringer Ingelheim GmbH - Charlesson LLC. - Chong Kun Dang Pharmaceutical Corp. - Circadian Technologies Limited - Clanotech AB - Clearside BioMedical, Inc. - Daiichi Sankyo Company, Limited - Eleven Biotherapeutics Inc. - Exonate Limited - F. Hoffmann-La Roche Ltd. - Formycon AG - GTx, Inc. - iCo Therapeutics Inc. - Icon Bioscience, Inc. - Kala Pharmaceuticals, Inc. - Mabion SA - Mitotech S.A. - Neurotech Pharmaceuticals, Inc. - Novartis AG - Ocular Therapeutix, Inc. - Ohr Pharmaceutical Inc. - Ophthotech Corp. - Oxford BioMedica Plc - PanOptica, Inc. - Pfenex Inc. - Pfizer Inc. - Quark Pharmaceuticals, Inc. - Regeneron Pharmaceuticals, Inc. - RegenxBio Inc. - RXi Pharmaceuticals Corporation - Santen Pharmaceutical Co., Ltd. - Sanwa Kagaku Kenkyusho Co., Ltd. - TRACON Pharmaceuticals, Inc. - TWi Pharmaceuticals, Inc. - Tyrogenex, Inc. - Xbrane Bioscience AB For more information visit http://www.researchandmarkets.com/research/rf...eovascular
CLSD: 6.90 (-0.20), PFE: 34.59 (+0.12), OPHT: 55.88 (+1.72), PFNX: 8.34 (+0.36), OCUL: 5.41 (+0.09), AGN: 233.51 (+4.96), GTXI: 0.60 (unch), OHRP: 2.74 (-0.02), AAVL: 4.14 (-0.18), TCON: 5.10 (+0.02), REGN: 357.14 (+5.22), NVS: 80.67 (+0.96)
Ophthotech Announces First Patient Dosed in Zimura(R) Phase 2/3 Study to Evaluate Treatment in Patients with Geographic Atrophy, an Advanced Form of Dry Age-Related Macular Degeneration
BusinessWire - Wed Jan 27, 6:30AM CST
Ophthotech Corporation (Nasdaq:OPHT) announced that the first patient has been dosed in a Phase 2/3 clinical study of Zimura(R) (avacincaptad pegol sodium), an inhibitor of complement factor C5, in patients with geographic atrophy, an advanced form of dry age-related macular degeneration (AMD). Complement factor C5 is a central component of the complement cascade believed to be involved in the development of AMD. The Phase 2/3 randomized, double-masked, controlled trial is designed to evaluate the safety and efficacy of Zimura(R) monotherapy in patients with geographic atrophy. The Company has also recently announced the initiation of a Phase 2 study of Zimura(R) in combination with anti-VEGF therapy in wet AMD patients to potentially reduce the treatment burden.
OPHT: 55.88 (+1.72)
Dry (Atrophic) Macular Degeneration therapeutics Pipeline Review, H2 2015
M2 - Fri Jan 22, 6:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/3cxkl2/dry_atrophic) has announced the addition of the "Dry (Atrophic) Macular Degeneration - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dry (Atrophic) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dry (Atrophic) Macular Degeneration and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Dry (Atrophic) Macular Degeneration Overview - Therapeutics Development - Pipeline Products for Dry (Atrophic) Macular Degeneration - Overview - Pipeline Products for Dry (Atrophic) Macular Degeneration - Comparative Analysis - Dry (Atrophic) Macular Degeneration - Therapeutics under Development by Companies - Dry (Atrophic) Macular Degeneration - Therapeutics under Investigation by Universities/Institutes - Dry (Atrophic) Macular Degeneration - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Dry (Atrophic) Macular Degeneration - Products under Development by Companies - Dry (Atrophic) Macular Degeneration - Products under Investigation by Universities/Institutes - Dry (Atrophic) Macular Degeneration - Companies Involved in Therapeutics Development - Aciont Inc. - Acucela Inc. - Alexion Pharmaceuticals, Inc. - Alimera Sciences, Inc. - Apellis Pharmaceuticals, Inc. - Benitec Biopharma Limited - Catalyst Biosciences, Inc. - Cell Cure Neurosciences, Ltd. - Foamix Pharmaceuticals Ltd. - Genentech, Inc. - GenSight Biologics SA - GlaxoSmithKline Plc - Icon Bioscience, Inc. - MacuCLEAR, Inc. - Novartis AG - Ocata Therapeutics, Inc. - Ophthotech Corp. - pSivida Corp. - R-Tech Ueno, Ltd. - StemCells, Inc. - Sun Pharma Advanced Research Company Ltd. - U.S. Stem Cell, Inc. For more information visit http://www.researchandmarkets.com/research/3c...y_atrophic
OCAT: 8.47 (+0.01), OPHT: 55.88 (+1.72), FOMX: 6.14 (-0.06), GNST: (), GSK: 42.56 (+0.80), ALIM: 1.49 (-0.02), ALXN: 123.57 (+2.16), CBIO: 1.42 (-0.03), NVS: 80.67 (+0.96)
Why Opthotech Corporation Shares Skyrocketed by 75% in 2015
Todd Campbell, The Motley Fool - Motley Fool - Sun Jan 10, 9:20AM CST
Source: National Eye Institute. W hat: A new adjunct therapy under development that could improve outcomes for people suffering from a form of age-related vision loss caused shares in Ophthotech Corporation to soar higher by 75% in 2015,...
OPHT: 55.88 (+1.72), REGN: 357.14 (+5.22), NVS: 80.67 (+0.96)
Ophthotech Announces Appointment of David E. Redlick to Its Board of Directors
BusinessWire - Wed Jan 06, 3:05PM CST
Ophthotech Corporation (Nasdaq: OPHT) today announced the appointment of David E. Redlick to its Board of Directors effective immediately.
OPHT: 55.88 (+1.72)
Glenn P. Sblendorio to Join Ophthotech as Executive Vice President, Chief Operating Officer and Chief Financial Officer
BusinessWire - Tue Jan 05, 6:30AM CST
Ophthotech Corporation (NASDAQ: OPHT) today announced that Glenn P. Sblendorio, a leading industry veteran, has agreed to join the Company as Executive Vice President, Chief Operating Officer and Chief Financial Officer on April 1, 2016. Mr. Sblendorio is joining Ophthotech from The Medicines Company, where he most recently served as President and Chief Financial Officer. Mr. Sblendorio has more than 30 years of experience in the life sciences sector and is widely known in the investment community and the biotechnology / pharmaceutical industry. He has held a variety of senior management positions at Hoffmann-LaRoche, Inc., Eyetech Pharmaceuticals Inc. and MPM Capital Advisors, LLC. Mr. Sblendorio has served as a member of the Board of Directors and the Audit Committee Chairman of Ophthotech. He will resign as a Director of Ophthotech effective with the assumption of his new executive position, and effective immediately, Mr. Sblendorio will no longer serve on the Audit Committee. Ophthotech also announced today that Michael G. Atieh is retiring as Executive Vice President and Chief Financial and Business Officer of the Company. The Company expects that Mr. Atieh's retirement will be effective as of April 1, 2016.
OPHT: 55.88 (+1.72)
Ophthotech Corporation to Present at the 34th Annual J.P. Morgan Healthcare Conference
BusinessWire - Mon Jan 04, 3:05PM CST
Ophthotech Corporation (NASDAQ: OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 11, 2016 at 2:30 p.m. Pacific Time (5:30 p.m. Eastern Time).
JPM: 64.05 (+1.34), OPHT: 55.88 (+1.72)
Ophthotech Corporation to Present at the Goldman Sachs 37th Annual Global Healthcare Conference
BusinessWire - Tue May 31, 6:30AM CDT
Ophthotech Corporation (NASDAQ:OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present at the Goldman Sachs 37th Annual Global Healthcare Conference in Rancho Palos Verdes, California on Tuesday June 7, 2016 at 8:40 a.m. PT (11:40 a.m. ET).
OPHT: 55.88 (+1.72)
What to Look for in These Biotech Stocks? Threshold Pharma, Seattle Genetics, Chiasma, and Ophthotech
PR Newswire - Wed May 18, 7:38AM CDT
The Biotech industry continues to face a wave of challenges, but it does not mean that there are no opportunities ahead. Today, ActiveWallSt.com has on its list these four equities: Threshold Pharmaceuticals Inc. (NASDAQ: THLD), Seattle Genetics Inc. (NASDAQ: SGEN), Chiasma Inc. (NASDAQ: CHMA), and Ophthotech Corp. (NASDAQ: OPHT). Sign up now to receive our free insights and trading alerts at:
SGEN: 40.07 (+0.96), OPHT: 55.88 (+1.72), THLD: 0.41 (+0.03), CHMA: 2.74 (+0.19)
pSivida CEO to Present at 2016 International Symposium of Ocular Pharmacology and Therapeutics
GlobeNewswire - Wed May 04, 7:00AM CDT
pSivida Corp. (NASDAQ
SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that Dr. Paul Ashton, president and CEO, will present "Changing the Treatment Paradigm through Innovative Drug Delivery" at the International Symposium of Ocular Pharmacology and Therapeutics (ISOPT) on Sunday, May 8, 2016 in Paris. OPHT: 55.88 (+1.72), PSDV: 3.20 (+0.26), PVA: 0.15 (-0.04)
Ophthotech reports 1Q loss
Automated Insights - Wed May 04, 6:38AM CDT
NEW YORK (AP) _ Ophthotech Corp. (OPHT) on Wednesday reported a first-quarter loss of $36.3 million, after reporting a profit in the same period a year earlier.
OPHT: 55.88 (+1.72)
Ophthotech Reports First Quarter 2016 Financial and Operating Results
BusinessWire - Wed May 04, 6:30AM CDT
Ophthotech Corporation (Nasdaq:OPHT) today announced financial results for the first quarter ended March 31, 2016 and provided an update on the Company's business and product development programs.
OPHT: 55.88 (+1.72)
Will AVEO Pharmaceuticals (AVEO) Surprise in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue May 03, 5:42PM CDT
AVEO Pharmaceuticals (AVEO) is expected to report first-quarter 2016 results on Mar 5.
ZTS: 47.90 (+0.57), OPHT: 55.88 (+1.72), AVEO: 0.98 (-0.01), NVS: 80.67 (+0.96)
Ophthotech Corporation to Report First Quarter 2016 Financial Results and Host Conference Call on Wednesday, May 4, 2016
BusinessWire - Tue Apr 26, 6:30AM CDT
Ophthotech Corporation (Nasdaq:OPHT) today announced that it will report its first quarter 2016 financial results on Wednesday, May 4, 2016. Following the announcement, Ophthotech's management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss the Company's financial results and provide a general business update.
OPHT: 55.88 (+1.72)
AVEO Gives AV-203 Ex-U.S. Rights to CANbridge Life Sciences
Zacks Equity Research - Zacks Investment Research - Wed Mar 23, 3:25AM CDT
AVEO Pharmaceuticals (AVEO) struck an exclusive collaboration and license agreement granting CANbridge Life Sciences rights to AV-203 outside North America.
BIIB: 238.62 (+4.02), OPHT: 55.88 (+1.72), AVEO: 0.98 (-0.01), NVS: 80.67 (+0.96)
Ophthotech Corporation to Present at Barclays Global Healthcare Conference 2016
BusinessWire - Tue Mar 08, 6:30AM CST
Ophthotech Corporation (NASDAQ:OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the Barclays Global Healthcare Conference 2016 in Miami on Tuesday, March 15, 2016 at 10:45 a.m. Eastern Time.
OPHT: 55.88 (+1.72)
Will AVEO (AVEO) Surprise Estimates in Q4 Earnings Again?
Zacks Equity Research - Zacks Investment Research - Wed Mar 02, 3:45PM CST
AVEO Pharmaceuticals (AVEO), which is expected to report fourth-quarter 2015 results on Mar 4, had recorded a positive earnings surprise of 200% last quarter.
BDSI: 2.39 (+0.06), OPHT: 55.88 (+1.72), AVEO: 0.98 (-0.01), NVS: 80.67 (+0.96)
Why Ophthotech Corporation Shares Tumbled 31% in January
Todd Campbell, The Motley Fool - Motley Fool - Sat Feb 06, 7:40AM CST
Source: Flickr user Luis Gustavo Zamudio A. W hat: Despite kicking off new trials in dry age-related macular degeneration, shares in Ophthotech Corporation dropped 31% in January, according to S&P Capital IQ. So what: In January,...
OPHT: 55.88 (+1.72), REGN: 357.14 (+5.22), NVS: 80.67 (+0.96)
Ophthotech Corporation to Present at the LEERINK Partners 5th Annual Global Healthcare Conference
BusinessWire - Wed Feb 03, 6:30AM CST
Ophthotech Corporation (NASDAQ:OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the LEERINK Partners 5th Annual Global Healthcare Conference in New York City on Wednesday, February 10, 2016 at 11:05 a.m. Eastern Time.
OPHT: 55.88 (+1.72)
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review 2015
M2 - Fri Jan 29, 10:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/rfl587/wet_neovascular) has announced the addition of the "Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Wet (Neovascular / Exudative) Macular Degeneration Overview - Therapeutics Development - Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration - Overview - Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration - Comparative Analysis - Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics under Development by Companies - Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics under Investigation by Universities/Institutes - Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Wet (Neovascular / Exudative) Macular Degeneration - Products under Development by Companies - Wet (Neovascular / Exudative) Macular Degeneration - Products under Investigation by Universities/Institutes - Wet (Neovascular / Exudative) Macular Degeneration - Companies Involved in Therapeutics Development Companies Mentioned: - Aciont Inc. - Allergan Plc - Amakem NV - Apellis Pharmaceuticals, Inc. - Apexigen, Inc. - Applied Genetic Technologies Corporatio - Avalanche Biotechnologies, Inc. - Benitec Biopharma Limited - BIOCAD - Boehringer Ingelheim GmbH - Charlesson LLC. - Chong Kun Dang Pharmaceutical Corp. - Circadian Technologies Limited - Clanotech AB - Clearside BioMedical, Inc. - Daiichi Sankyo Company, Limited - Eleven Biotherapeutics Inc. - Exonate Limited - F. Hoffmann-La Roche Ltd. - Formycon AG - GTx, Inc. - iCo Therapeutics Inc. - Icon Bioscience, Inc. - Kala Pharmaceuticals, Inc. - Mabion SA - Mitotech S.A. - Neurotech Pharmaceuticals, Inc. - Novartis AG - Ocular Therapeutix, Inc. - Ohr Pharmaceutical Inc. - Ophthotech Corp. - Oxford BioMedica Plc - PanOptica, Inc. - Pfenex Inc. - Pfizer Inc. - Quark Pharmaceuticals, Inc. - Regeneron Pharmaceuticals, Inc. - RegenxBio Inc. - RXi Pharmaceuticals Corporation - Santen Pharmaceutical Co., Ltd. - Sanwa Kagaku Kenkyusho Co., Ltd. - TRACON Pharmaceuticals, Inc. - TWi Pharmaceuticals, Inc. - Tyrogenex, Inc. - Xbrane Bioscience AB For more information visit http://www.researchandmarkets.com/research/rf...eovascular
CLSD: 6.90 (-0.20), PFE: 34.59 (+0.12), OPHT: 55.88 (+1.72), PFNX: 8.34 (+0.36), OCUL: 5.41 (+0.09), AGN: 233.51 (+4.96), GTXI: 0.60 (unch), OHRP: 2.74 (-0.02), AAVL: 4.14 (-0.18), TCON: 5.10 (+0.02), REGN: 357.14 (+5.22), NVS: 80.67 (+0.96)
Ophthotech Announces First Patient Dosed in Zimura(R) Phase 2/3 Study to Evaluate Treatment in Patients with Geographic Atrophy, an Advanced Form of Dry Age-Related Macular Degeneration
BusinessWire - Wed Jan 27, 6:30AM CST
Ophthotech Corporation (Nasdaq:OPHT) announced that the first patient has been dosed in a Phase 2/3 clinical study of Zimura(R) (avacincaptad pegol sodium), an inhibitor of complement factor C5, in patients with geographic atrophy, an advanced form of dry age-related macular degeneration (AMD). Complement factor C5 is a central component of the complement cascade believed to be involved in the development of AMD. The Phase 2/3 randomized, double-masked, controlled trial is designed to evaluate the safety and efficacy of Zimura(R) monotherapy in patients with geographic atrophy. The Company has also recently announced the initiation of a Phase 2 study of Zimura(R) in combination with anti-VEGF therapy in wet AMD patients to potentially reduce the treatment burden.
OPHT: 55.88 (+1.72)
Dry (Atrophic) Macular Degeneration therapeutics Pipeline Review, H2 2015
M2 - Fri Jan 22, 6:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/3cxkl2/dry_atrophic) has announced the addition of the "Dry (Atrophic) Macular Degeneration - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dry (Atrophic) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dry (Atrophic) Macular Degeneration and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Dry (Atrophic) Macular Degeneration Overview - Therapeutics Development - Pipeline Products for Dry (Atrophic) Macular Degeneration - Overview - Pipeline Products for Dry (Atrophic) Macular Degeneration - Comparative Analysis - Dry (Atrophic) Macular Degeneration - Therapeutics under Development by Companies - Dry (Atrophic) Macular Degeneration - Therapeutics under Investigation by Universities/Institutes - Dry (Atrophic) Macular Degeneration - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Dry (Atrophic) Macular Degeneration - Products under Development by Companies - Dry (Atrophic) Macular Degeneration - Products under Investigation by Universities/Institutes - Dry (Atrophic) Macular Degeneration - Companies Involved in Therapeutics Development - Aciont Inc. - Acucela Inc. - Alexion Pharmaceuticals, Inc. - Alimera Sciences, Inc. - Apellis Pharmaceuticals, Inc. - Benitec Biopharma Limited - Catalyst Biosciences, Inc. - Cell Cure Neurosciences, Ltd. - Foamix Pharmaceuticals Ltd. - Genentech, Inc. - GenSight Biologics SA - GlaxoSmithKline Plc - Icon Bioscience, Inc. - MacuCLEAR, Inc. - Novartis AG - Ocata Therapeutics, Inc. - Ophthotech Corp. - pSivida Corp. - R-Tech Ueno, Ltd. - StemCells, Inc. - Sun Pharma Advanced Research Company Ltd. - U.S. Stem Cell, Inc. For more information visit http://www.researchandmarkets.com/research/3c...y_atrophic
OCAT: 8.47 (+0.01), OPHT: 55.88 (+1.72), FOMX: 6.14 (-0.06), GNST: (), GSK: 42.56 (+0.80), ALIM: 1.49 (-0.02), ALXN: 123.57 (+2.16), CBIO: 1.42 (-0.03), NVS: 80.67 (+0.96)
Why Opthotech Corporation Shares Skyrocketed by 75% in 2015
Todd Campbell, The Motley Fool - Motley Fool - Sun Jan 10, 9:20AM CST
Source: National Eye Institute. W hat: A new adjunct therapy under development that could improve outcomes for people suffering from a form of age-related vision loss caused shares in Ophthotech Corporation to soar higher by 75% in 2015,...
OPHT: 55.88 (+1.72), REGN: 357.14 (+5.22), NVS: 80.67 (+0.96)
Ophthotech Announces Appointment of David E. Redlick to Its Board of Directors
BusinessWire - Wed Jan 06, 3:05PM CST
Ophthotech Corporation (Nasdaq: OPHT) today announced the appointment of David E. Redlick to its Board of Directors effective immediately.
OPHT: 55.88 (+1.72)
Glenn P. Sblendorio to Join Ophthotech as Executive Vice President, Chief Operating Officer and Chief Financial Officer
BusinessWire - Tue Jan 05, 6:30AM CST
Ophthotech Corporation (NASDAQ: OPHT) today announced that Glenn P. Sblendorio, a leading industry veteran, has agreed to join the Company as Executive Vice President, Chief Operating Officer and Chief Financial Officer on April 1, 2016. Mr. Sblendorio is joining Ophthotech from The Medicines Company, where he most recently served as President and Chief Financial Officer. Mr. Sblendorio has more than 30 years of experience in the life sciences sector and is widely known in the investment community and the biotechnology / pharmaceutical industry. He has held a variety of senior management positions at Hoffmann-LaRoche, Inc., Eyetech Pharmaceuticals Inc. and MPM Capital Advisors, LLC. Mr. Sblendorio has served as a member of the Board of Directors and the Audit Committee Chairman of Ophthotech. He will resign as a Director of Ophthotech effective with the assumption of his new executive position, and effective immediately, Mr. Sblendorio will no longer serve on the Audit Committee. Ophthotech also announced today that Michael G. Atieh is retiring as Executive Vice President and Chief Financial and Business Officer of the Company. The Company expects that Mr. Atieh's retirement will be effective as of April 1, 2016.
OPHT: 55.88 (+1.72)
Ophthotech Corporation to Present at the 34th Annual J.P. Morgan Healthcare Conference
BusinessWire - Mon Jan 04, 3:05PM CST
Ophthotech Corporation (NASDAQ: OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 11, 2016 at 2:30 p.m. Pacific Time (5:30 p.m. Eastern Time).
JPM: 64.05 (+1.34), OPHT: 55.88 (+1.72)
